Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-two ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, sixteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $267.60.
Several brokerages have commented on AXSM. Morgan Stanley raised their price objective on Axsome Therapeutics from $242.00 to $251.00 and gave the company an “equal weight” rating in a report on Tuesday. BMO Capital Markets started coverage on Axsome Therapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $310.00 target price for the company. Guggenheim increased their target price on Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada cut their price target on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a report on Tuesday.
Check Out Our Latest Analysis on Axsome Therapeutics
Insider Activity at Axsome Therapeutics
Institutional Investors Weigh In On Axsome Therapeutics
Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after acquiring an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after acquiring an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after acquiring an additional 84,151 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Axsome Therapeutics during the first quarter worth approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after purchasing an additional 17,250 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Trading Down 0.0%
AXSM stock opened at $213.67 on Thursday. Axsome Therapeutics has a 52-week low of $108.04 and a 52-week high of $260.19. The company has a quick ratio of 1.32, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. The firm has a market cap of $11.19 billion, a P/E ratio of -56.98 and a beta of 0.65. The company’s 50-day simple moving average is $235.53 and its 200-day simple moving average is $205.05.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The business had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. As a group, equities analysts forecast that Axsome Therapeutics will post -2.7 EPS for the current fiscal year.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome’s pipeline includes several late-stage and approved product candidates.
Featured Stories
- Five stocks we like better than Axsome Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
